Liquidia Technologies, Inc. (LQDA) shares rallied 14.1% in the last trading session to close at $10.16. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 33% loss over the past four weeks. The sudden rise in the stock price was observed after Liquidia announced the pricing of an underwritten public offering and a concurrent private placement which is expected to raise gross proceeds of approximately $67.5 milli ...

MORRISVILLE, N.C., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (the "Company" or "Liquidia"), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the pricing of an underwritten public offering and a concurrent private placement, with anticipated total gross proceeds of approximately $67.5 million, before deducting underwriting discounts and commissions, and expenses. The Company offered 6,460,674 shares of co ...

MORRISVILLE, N.C., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present at the following investor conferences this September: 2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, from 11:00 – 11:35 a.m. ET 2024 Cantor Global Healthcare Conference in New York on Thursday, September 19, 2024, from 1:30 – 1:50 p.m ...

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA) on behalf of Liquidia stockholders. Our investigation concerns whether Liquidia has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 19, 2024, Liquidia issued a press release announcing ...

NEW YORK, Aug. 26, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Liquidia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On August 19, 2024 ...

MORRISVILLE, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it has filed litigation in the U.S. District Court of the District of Columbia (Case No. 1:24- cv-02428) that challenges the recent decision by the United States Food and Drug Administration (FDA) to grant 3-year new clinical investigation exclusivity (NCI exclusivity) to Tyvaso DPI®. FDA gra ...

Shares of Liquidia Corporation (LQDA) lost nearly 31% on Monday after the FDA delayed granting full approval to its Yutrepia (treprostinil) inhalation powder in a pair of lung disorder indications. The FDA granted tentative approval to Yutrepia for a second indication — in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug was initially granted tentative approval for use in adults with pulmonary arterial hypertension (PAH) in 2021. A tentative approval indicates ...

BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Liquidia Corp. (Nasdaq: LQDA) for potential securities law violations. Investors who have lost money in their Liquidia Corp. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/lqda. What is this all about? Liquidia shares have dropped 35% today following an announcement that the FDA has postponed final approval of Liquidia's Yutrepia drug ...

U.S. stock futures were slightly higher this morning, with the S&P 500 futures gaining around 0.1% on Monday. Shares of Liquidia Corporation LQDA fell sharply in today's pre-market trading. The company announced that the FDA granted tentative approval of YUTREPIA inhalation powder to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia shares dipped 36.3% to $8.98 in pre-market trading. Here are some big stocks recording losses in t ...

文章核心观点 - FDA已经确认Liquidia公司提交的YUTREPIA新药申请(NDA)修正案是合适的,并且该申请满足联邦食品、药品和化妆品法案的批准要求 [1] - FDA已经给予YUTREPIA临时批准,用于治疗成人肺动脉高压(PAH)和肺间质性肺病相关肺高压(PH-ILD) [2] - 临时批准表明YUTREPIA在质量、安全性和有效性方面已满足所有监管标准,但需要等待竞争产品的监管独占期到期后才能获得最终批准 [2] - Liquidia公司对FDA同时授予United Therapeutics公司Tyvaso DPI三年监管独占期的决定表示失望和不同意,并计划采取行动来挑战这一决定 [3] - YUTREPIA的临时批准是基于INSPIRE III期临床试验的结果,该试验评估了既往未使用过曲美布汀的患者,以及从曲美布汀雾化吸入剂转换到YUTREPIA的患者 [4] - FDA的批准还确认了YUTREPIA的生产、检测和供应链信息符合质量和安全的GMP监管标准 [4] - Liquidia公司致力于满足PAH和PH-ILD患者的未满足需求,并将尽快获得YUTREPIA的最终批准 [5] 行业概况 肺动脉高压(PAH) - PAH是一种罕见的慢性进行性疾病,导致肺动脉硬化和狭窄,可能导致右心衰竭和死亡 [6] - 美国目前估计有45,000名PAH患者被诊断和接受治疗,目前还没有治愈PAH的方法,现有治疗的目标是缓解症状、维持或改善功能分级、延缓疾病进展和改善生活质量 [6] 肺间质性肺病相关肺高压(PH-ILD) - PH-ILD包括多达150种不同的肺部疾病,如间质性肺纤维化、慢性过敏性肺炎、结缔组织病相关ILD和慢性肺纤维化合并肺气肿等 [7] - 美国目前估计有超过60,000名PH-ILD患者,但由于诊断不足和直到2021年3月才有首个获批治疗药物,许多ILD疾病的患者群体规模尚不清楚 [7] YUTREPIA简介 - YUTREPIA是一种吸入式曲美布汀干粉制剂,采用Liquidia公司的PRINT®技术开发,可以制造出尺寸、形状和成分精确一致的药物颗粒,有利于肺部沉积 [8] - YUTREPIA已完成INSPIRE III期临床试验,评估了既往未使用过曲美布汀的PAH患者,以及从曲美布汀雾化吸入剂转换到YUTREPIA的患者 [8][9] - YUTREPIA目前正在ASCENT试验中评估其在PH-ILD患者中的剂量和耐受性 [9] - Liquidia公司除了YUTREPIA,还在开发L606,这是一种曲美布汀缓释制剂,需要使用新一代雾化器给药 [10]